PEAnut Anaphylaxis Predictors

NCT02424136 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-01-22

No results posted yet for this study

Summary

Peanut allergy can be life-threatening. Current diagnostic techniques for peanut allergy have high sensitivity, but not high specificity. This clinical trial will test the validity of a novel blood biomarker (compared with current testing) as a diagnostic predictor of anaphylaxis to peanut.

Conditions

Interventions

OTHER

Questionnaire

5 minute questionnaire focused on symptoms of allergic disease

OTHER

Peanut Skin prick test

Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual

OTHER

Fraction of exhaled nitric oxide

Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).

OTHER

Spirometry

Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).

OTHER

Serum Peanut and Ara h2 specific immunoglobulin E

Peanut and Ara h2 specific IgE antibodies

OTHER

Collection of blood biomarker

Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge

OTHER

Peanut food challenge

Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report

Sponsors & Collaborators

  • Hunter Medical Research Institute, Australia

    collaborator UNKNOWN
  • University of Newcastle, Australia

    collaborator OTHER
  • Thrasher Research Fund

    collaborator OTHER
  • Hunter Childrens Research Foundation, Australia

    collaborator UNKNOWN
  • Aerocrine AB

    collaborator INDUSTRY
  • John Hunter Children's Hospital

    lead OTHER

Principal Investigators

  • Joerg Mattes, MD · John Hunter Children's Hospital, Australia

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-22
Primary Completion
2018-08-28
Completion
2019-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02424136 on ClinicalTrials.gov